CVM•benzinga•
Cel-Sci shares are trading higher after the company announced it is in the final stages of its 212-patient confirmatory registration study of Multikine.
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 20, 2025 by benzinga